muramylnac-ala-isogln-lys-tripeptide has been researched along with Canine Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubielzig, RR; Fox, LE; Helfand, SC; Keller, ET; Kurzman, ID; MacEwen, EG; Madewell, BR; Rodriguez, CO; Rosenthal, RC; Vail, DM | 1 |
| Dubielzig, RR; Everlith, K; Fidel, J; Fox, LE; Henry, C; Kurzman, ID; MacEwen, EG; Madewell, BR; Obradovich, J; Phillips, B; Rodriguez, CO; Rosenberg, M; Rosenthal, RC; Vail, DM; Zwahlen, CH | 1 |
2 trial(s) available for muramylnac-ala-isogln-lys-tripeptide and Canine Diseases
| Article | Year |
|---|---|
Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dog Diseases; Dogs; Double-Blind Method; Drug Carriers; Female; Liposomes; Male; Osteosarcoma | 1995 |
Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Combined Modality Therapy; Cytotoxicity Tests, Immunologic; Dog Diseases; Dogs; Double-Blind Method; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Liposomes; Male; Melanoma; Mouth Neoplasms; Survival Analysis | 1999 |